Mutations in the p53 Tumor Suppressor Gene: Clues to Cancer Etiology and Molecular Pathogenesis

Cancer Research

Volumn 54, Issue 18, 1994, Pages 4855-4878

  Greenblatt, M S ^a   Bennett, W P ^a   Harris, C C ^a   Hollstein, M ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b German Cancer Research Center ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

CANCER GENETICS; CARCINOGENESIS; CIGARETTE SMOKING; DNA REPAIR; DNA REPLICATION; GENE MUTATION; GENETIC ANALYSIS; HOUSEKEEPING GENE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PREVALENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; TUMOR SUPPRESSOR GENE;

AFLATOXINS; ANIMAL; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME DELETION; CONSERVED SEQUENCE; DISEASE MODELS, ANIMAL; DNA DAMAGE; DNA MUTATIONAL ANALYSIS; DNA REPAIR; DNA REPLICATION; GENES, P53; HEPATITIS B; HUMAN; MUTATION; NEOPLASMS; NEOPLASMS, RADIATION-INDUCED; PHENOTYPE; PROTEIN P53; SEQUENCE ANALYSIS, DNA; SMOKING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0028071555     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (288)

1. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers. Science (Washington DC), 253: 49–53, 1991.
2. Levine, A. J., Momand, J., and Finlay, C. A. The p53 tumour suppressor gene. Nature (Lond.), 351: 453–456, 1991.
3. Harris, C. C. The p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology and cancer risk assessment. Science (Wash-ington DC), 262: 1980–1981, 1993.
4. Harris, C. C., and Hollstein, M. Clinical implications of the p53 tumor-suppressor gene. N. Engl. J. Med., 329: 1318–1327, 1993.
5. Vogelstein, B., and Kinzler, K. W. p53 function and dysfunction. Cell, 70: 523–526, 1992.
6. Montenarh, M. Functional implications of the growth-suppressor/oncoprotein p53. Int. J. Oncol., 1: 37–45, 1992.
7. Lindahl, T. Instability and decay of the primary structure of DNA. Nature (Lond.), 362: 709–715, 1993.
8. Kunkel, T. A. Nucleotide repeats. Slippery DNA and diseases. Nature (Lond.), 365: 207–208, 1993.
9. Holliday, R., and Grigg, G. W. DNA methylation and mutation. Mutat. Res., 285: 61–67, 1993.
10. Strauss, B. The origin of point mutations in human tumor cells. Cancer Res., 52: 249–253, 1992.
11. Ehrlich, M., Zhang, X. Y., and Inamdar, N. M. Spontaneous deamination of cytosine and 5-methylcytosine residues in DNA and replacement of 5-methylcytosine residues with cytosine residues. Mutat. Res., 238: 277–286, 1990.
12. Loeb, L. A., and Cheng, K. C. Errors in DNA synthesis: a source of spontaneous mutations. Mutat. Res., 238: 297–304, 1990.
13. Loeb, L. A., and Preston, B. D. Mutagenesis by apurinic/apyrimidinic sites. Annu. Rev. Genet., 20: 201–230, 1986.
14. Lutz, W. K. Endogenous genotoxic agents and processes as a basis of spontaneous carcinogenesis. Mutat. Res., 238: 287–295, 1990.
15. Breimer, L. H. Molecular mechanisms of oxygen radical carcinogenesis and mutagenesis: the role of DNA base damage. Mol. Carcinog., 3: 188–197, 1990.
16. Rideout, W. M., III, Coetzee, G. A., Olumi, A. F., and Jones, P. A. 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science (Washington DC), 249: 1288–1290, 1990.
17. Kunkel, T. A. Misalignment-mediated DNA synthesis errors. Biochemistry, 29: 8003–8011, 1990.
18. Phear, G., Nalbantoglu, J., and Meuth, M. Next-nucleotide effects in mutations driven by DNA precursor pool imbalances at the aprt locus of Chinese hamster ovary cells. Proc. Natl. Acad. Sci. USA, 84: 4450–4454, 1987.
19. Liu, P. K., Chang, C. C., Trosko, J. E., Dube, D. K., Martin, G. M., and Loeb, L. A. Mammalian mutator mutant with an aphidicolin-resistant DNA polymerase a. Proc. Natl. Acad. Sci. USA, 80: 797–801, 1983.
20. Loeb, L. A., Springgate, C. F., and Battula, N. Errors in DNA replication as a basis of malignant changes. Cancer Res., 34: 2311–2321, 1974.
21. Nowell, P. C. The clonal evolution of tumor cell populations. Science (Washington DC), 194: 23–28, 1976.
22. Foulds, L. The experimental study of tumor progression: a review. Cancer Res., 14: 317–339, 1954.
23. Chorazy, M. Sequence rearrangements and genome instability. A possible step in carcinogenesis. J. Cancer Res. Clin. Oncol., 109: 159–172, 1985.
24. German, J. Bloom's syndrome. X. The cancer proneness points to chromosome mutation as a crucial event in human neoplasia. In: J. German (ed.), Chromosome Mutation and Neoplasia, pp. 347–357. New York: Alan R. Liss, 1983.
25. Fishel, R., Lescoe, M. K., Rao, M. R., Copeland, N. G., Jenkins, N. A., Garber, J., Kane, M., and Kolodner, R. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell, 75: 1027–1038, 1993.
26. Leach, F. S., Nicolaides, N. C., Papadopoulos, N., et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell, 75: 1215–1235, 1993.
27. Bronner, C. E., Baker, S. M., Morrison, P. T., et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature (Lond.), 368: 258–261, 1994.
28. Papadopoulos, N., Nicolaides, N. C., Wei, Y. F., et al. Mutation of a mutL homolog in hereditary colon cancer. Science (Washington DC), 263: 1625–1629, 1994.
29. Ionov, Y., Peinado, M. A., Malkhosyan, S., Shibata, D., and Perucho, M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature (Lond.), 363: 558–561, 1993.
30. Yuspa, S. H., and Poirier, M. C. Chemical carcinogenesis: from animal models to molecular models in one decade. Adv. Cancer Res., 50: 25–70, 1988.
31. Horsfall, M. J., Gordon, A. J., Burns, P. A., Zielenska, M., van der Vliet, G. M., and Glickman, B. W. Mutational specificity of alkylating agents and the influence of DNA repair. Environ. Mol. Mutagen., 15: 107–122, 1990.
32. Strauss, B.S. The “A rule” of mutagen specificity: a consequence of DNA polymerase bypass of non-instructional lesions? Bioessays, 13: 79–84, 1991.
33. Basu, A. K., and Essigmann, J. M. Site specifically modified oligodeoxynucleotides as probes for the structural and biological effects of DNA-damaging agents. Chem. Res. Toxicol., 1: 1–18, 1988.
34. Skandalis, A., and Glickman, B. W. Endogenous gene systems for the study of mutational specificity in mammalian cells. Cancer Cells, 2: 79–83, 1990.
35. Vogelstein, B., and Kinzler, K. W. Carcinogens leave fingerprints. Nature (Lond.), 355: 209–210, 1992.
36. Sarasin, A. Use of shuttle vectors for the analysis of DNA damage processing in mammalian cells. Mutat. Res., 220: 101–106, 1989.
37. Miller, J. H. Carcinogens induce targeted mutations in Escherichia coli. Cell, 31: 5-7, 1982.
38. Mazur, M., Gordon, A. J. F., Bernelot-Moens, C., and Glickman, B. W. Comparison of the mutational specificities exhibited by BPDE in Escherichia coli and CHO cells. In: M. W. Lambert and J. Laval (eds.), DNA Repair Mechanisms and their Biological Implications in Mammalian Cells, pp 205–231. New York: Plenum Publishing Corp., 1989.
39. Grosovsky, A. J., de Boer, J. G., de Jong, P. J., Drobetsky, E. A., and Glickman, B. W. Base substitutions, frameshifts, and small deletions constitute ionizing radiation-induced point mutations in mammalian cells. Proc. Natl. Acad. Sci. USA, 85: 185–188, 1988.
40. Liber, H. L., Call, K. M., and Little, J. B. Molecular and biochemical analyses of spontaneous and X-ray-induced mutants in human lymphoblastoid cells. Mutat. Res., 178: 143–153, 1987.
41. Yang, J. L., Chen, R. H., Maher, V. M., and McCormick, J. J. Kinds and location of mutations induced by (±)-7β,8α-dihydroxy-9α,10α-epoxy-7,8,9,10-tetrahydro-ben-zo[a]pyrene in the coding region of the hypoxanthine (guanine) phosphoribosyl transferase gene in diploid human fibroblasts. Carcinogenesis (Lond.), 12: 71–75, 1991.
42. Albertini, R. J., Sullivan, L. M., Berman, J. K., Greene, C. J., Stewart, J. A., Silveira, J. M., and O’Neill, J. P. Mutagenicity monitoring in humans by autoradiographic assay for mutant T-lymphocytes. Mutat. Res., 204: 481–492, 1988.
43. Cariello, N. F., Craft, T. R., Vrieling, H., Van Zeeland, A. A., Adams, T., and Skopek, T. R. Human HPRT mutant database: software for data entry and retrieval. Environ. Mol. Mutagen., 20: 81–83, 1992.
44. Kress, S., Sutter, C., Strickland, P. T., Mukhtar, H., Schweizer, J., and Schwarz, M. Carcinogen-specific mutational pattern in the p53 gene in ultraviolet B radiation-induced squamous cell carcinomas of mouse skin. Cancer Res., 52: 6400–6403, 1992.
45. Kanjilal, S., Pierceall, W. E., Cummings, K. K., Kripke, M. L., and Ananthaswamy, H. N. High frequency of p53 mutations in ultraviolet radiation-induced murine skin tumors: evidence for strand bias and tumor heterogeneity. Cancer Res., 53: 2961–2964, 1993.
46. Ruggeri, B., DiRado, M., Zhang, S. Y., Bauer, B., Goodrow, T., and Klein-Szanto, A. J. P. Benzo(a)pyrene-induced murine skin tumors exhibit frequent and characteristic G to T mutations in the p53 gene. Proc. Natl. Acad. Sci. USA, 90: 1013–1017, 1993.
47. Ruggeri, B., Caamano, J., Goodrow, T., DiRado, M., Bianchi, A., Trono, D., Conti, C. J., and Klein-Szanto, A. J. Alterations of the p53 tumor suppressor gene during mouse skin tumor progression. Cancer Res., 51: 6615–6621, 1991.
48. Burns, P. A., Kemp, C. J., Gannon, J. V., Lane, D. P., Bremner, R., and Balmain, A. Loss of heterozygosity and mutational alterations of the p53 gene in skin tumours of interspecific hybrid mice. Oncogene, 6: 2363–2369, 1991.
49. Shields, P. G., and Harris, C. C. Molecular epidemiology and the genetics of environmental cancer. JAMA, 266: 681–687, 1991.
50. Hollstein, M., Rice, K., Greenblatt, M. S., Soussi, T., Fuchs, R., Sorlie, T., Hovig, E., Smith-Sorensen, B., Montesano, R., and Harris, C. C. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res., 22(Supp.): in press, 1994.
51. Soussi, T., Caron de Fromentel, C., and May, P. Structural aspects of the p53 protein in relation to gene evolution. Oncogene, 5: 945–952, 1990.
52. Park, M., and Vande Woude, G. F. Principles of molecular cell biology of cancer: oncogenes. In: V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer. Principles and Practice of Oncology, Ed. 3, pp. 45–66. New York: J. B. Lippincott Co., 1989.
53. Maesawa, C., Tamura, G., Suzuki, Y., Ishida, K., Saito, K., and Satodate, R. Sensitive detection of p53 gene mutations in esophageal endoscopic biopsy specimens by cell sorting combined with polymerase chain reaction single-strand conformation polymorphism analysis. Jpn. J. Cancer Res., 83: 1253–1256, 1992.
54. Tamura, G., Kihana, T., Nomura, K., Terada, M., Sugimura, T., and Hirohashi, S. Detection of frequent p53 gene mutations in primary gastric cancer by cell sorting and polymerase chain reaction single-strand conformation polymorphism analysis. Cancer Res., 51: 3056–3058, 1991.
55. Nigro, J. M., Baker, S. J., Preisinger, A. C., et al. Mutations in the p53 gene occur in diverse human tumor types. Nature (Lond.), 342: 705–708, 1989.
56. Hsu, I. C., Metcalf, R. A., Sun, T., Welsh, J., Wang, N. J., and Harris, C. C. p53 gene mutational hotspot in human hepatocellular carcinomas from Qidong, China. Nature (Lond.), 350: 427–428, 1991.
57. Hinds, P. W., Finlay, C. A., Quartin, R. S., Baker, S. J., Fearon, E. R., Vogelstein, B., and Levine, A. J. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the “hot spot: mutant phenotypes”. Cell Growth & Differ., 1: 571–580, 1990.
58. Hall, P. A., and Lane, D. P. p53 in tumour pathology: can we trust immunohistochemistry?—revisited. J. Pathol., 172: 1–4, 1994.
59. Castresana, J. S., Rubio, M. P., Vazquez, J. J., Idoate, M., Sober, A. J., Seizinger, B. R., and Barnhill, R. L. Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma. Int. J. Cancer, 55: 562–565, 1993.
60. Weiss, J., Schwechheimer, K., Cavenee, W. K., Herlyn, M., and Arden, K. C. Mutation and expression of the p53 gene in malignant melanoma cell lines. Int. J. Cancer, 54: 693–699, 1993.
61. Heimdal, K., Lothe, R. A., Lystad, S., Holm, R., Fossa, S. D., and Borresen, A. L. No germline TP53 mutations detected in familial and bilateral testicular cancer. Genes Chromosom. Cancer (Phila.), 6: 92–97, 1993.
62. Peng, H. Q., Hogg, D., Malkin, D., Bailey, D., Gallie, B. L., Bulbul, M., Jewett, M., Buchanan, J., and Goss, P. E. Mutations of the p53 gene do not occur in testis cancer. Cancer Res., 53: 3574–3578, 1993.
63. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817–825, 1993.
64. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K., and Elledge, S. J. The p21 cdk-interacting protein Cip 1 is a potent inhibitor of G, cyclin-dependent kinases. Cell, 75: 805–816, 1993.
65. Orita, M., Iwahana, H., Kanazawa, H., Hayashi, K., and Sekiya, T. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc. Natl. Acad. Sci USA, 86: 2766–2770, 1989.
66. Murakami, Y., Hayashi, K., and Sekiya, T. Detection of aberrations of the p53 alleles and the gene transcript in human tumor cell lines by single-strand conformation polymorphism analysis. Cancer Res., 51: 3356–3361, 1991.
67. Mitsudomi, T., Steinberg, S. M., Nau, M. M., et al. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene, 7: 171–180, 1992.
68. Borresen, A. L., Hovig, E., Smith-Sorensen, B., Malkin, D., Lystad, S., Andersen, T. I., Nesland, J. M., Isselbacher, K. J., and Friend, S. H. Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations. Proc. Natl. Acad. Sci. USA, 88: 8405–8409, 1991.
69. Smith-Sorensen, B., Gebhardt, M. C., Kloen, P., McIntyre, J., Aguilar, F., Cerutti, P., and Borresen, A. L. Screening for TP53 mutations in osteosarcomas using constant denaturant gel electrophoresis (CDGE). Hum. Mutat., 2: 274–285, 1993.
70. Condie, A., Eeles, R., Borresen, A. L., Coles, C., Cooper, C., and Prosser, J. Detection of point mutations in the p53 gene: comparison of single-strand conformation polymorphism, constant denaturant gel electrophoresis, and hydroxylamine and osmium tetroxide techniques. Hum. Mutat., 2: 58–66, 1993.
71. Matlashewski, G. J., Tuck, S., Pim, D., Lamb, P., Schneider, J., and Crawford, L. V. Primary structure polymorphism at amino acid residue 72 of human p53. Mol. Cell. Biol., 7: 961–963, 1987.
72. Carbone, D., Chiba, I., and Mitsudomi, T. Polymorphism at codon 213 within the p53 gene. Oncogene, 6: 1691–1692, 1991.
73. Eckert, K. A., and Kunkel, T. A. The fidelity of DNA polymerases used in the polymerase chain reactions. In: M. J. McPherson, P. Quirke, and G. R. Taylor (eds.), PCR: A Practical Approach, pp. 225–245. New York: Oxford University Press, 1991.
74. Jackson, D. P., Hayden, J. D., and Quirke, P. Extraction of nucleic acid from fresh and archival material. In: M. J. McPherson, P. Quirke, and G. R. Taylor (eds.), PCR: A Practical Approach, pp. 29–50. New York: Oxford University Press, 1991.
75. Bohr, V. A., Phillips, D. H., and Hanawalt, P. C. Heterogeneous DNA damage and repair in the mammalian genome. Cancer Res., 47: 6426–6436, 1987.
76. Xanthoudakis, S., Miao, G., Wang, F., Pan, Y. C., and Curran, T. Redox activation of Fos-Jun DNA binding activity is mediated by a DNA repair enzyme. EMBO J., 11: 3323–3335, 1992.
77. Schaeffer, L., Roy, R., Humbert, S., Moncollin, V., Vermeulen, W., Hoeijmakers, J. H., Chambon, P., and Egly, J. M. DNA repair helicase: a component of BTF2 (TFIIH) basic transcription factor. Science (Washington DC), 260: 58–63, 1993.
78. Evans, M. K., Taffe, B. G., Harris, C. C., and Bohr, V. A. DNA strand bias in the repair of the p53 gene in normal human and xeroderma pigmentosum group C fibroblasts. Cancer Res., 53: 5377–5381, 1993.
79. Bohr, V. A. Gene specific DNA repair. Carcinogenesis (Lond.), 12: 1983–1992, 1991.
80. Sato, M., Nishigori, C., Zghal, M., Yagi, T., and Takebe, H. Ultraviolet-specific mutations in p53 gene in skin tumors in xeroderma pigmentosum patients. Cancer Res., 53: 2944–2946, 1993.
81. Dumaz, N., Drougard, C., Sarasin, A., and Daya-Grosjean, L. Specific UV-induced mutation spectrum in the p53 gene of skin tumors from DNA-repair-deficient xeroderma pigmentosum patients. Proc. Natl. Acad. Sci. USA, 90: 10529–10533, 1993.
82. Gupta, P. K., Johnson, D. L., Reid, T. M., Lee, M. S., Romano, L. J., and King, C. M. Mutagenesis by single site-specific arylamine-DNA adducts. Induction of mutations at multiple sites. J. Biol. Chem., 264: 20120–20130, 1989.
83. Klein, J. C., Bleeker, M. J., Lutgerink, J. T., et al. Use of shuttle vectors to study the molecular processing of defined carcinogen-induced DNA damage: mutagenicity of single O4-ethylthymine adducts in HeLa cells. Nucleic Acids Res., 18: 4131–4137, 1990.
84. Moriya, M. Single-stranded shuttle phagemid for mutagenesis studies in mammalian cells: 8-oxoguanine in DNA induces targeted G. C→ T.A transversions in simian kidney cells. Proc. Natl. Acad. Sci USA, 90: 1122–1126, 1993.
85. Harris, C. C. Chemical and physical carcinogenesis: advances and perspectives. Cancer Res., 51: 5023s-5044s, 1991.
86. Hussain, S. P., Aguilar, F., and Cerutti, P. Mutagenesis of codon 248 of the human p53 tumor suppressor gene by N-ethyl-N-nitrosourea. Oncogene, 9: 13–18, 1994.
87. Fraumeni, J. F., Hoover, R. N., Devesa, S. S., and Kinlen, L. J. Epidemiology of cancer. In: V. T. DeVita, S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principle and Practice of Oncology, pp. 150–181. Philadelphia: J. B. Lippincott, 1993.
88. Jego, N., Thomas, G., and Hamelin, R. Short direct repeats flanking deletions, and duplicating insertions in p53 gene in human cancers. Oncogene, 8: 209–213, 1993.
89. Krawczak, M., and Cooper, D. N. Gene deletions causing human genetic disease: mechanisms of mutagenesis and the role of the local DNA sequence environment. Hum. Genet., 86: 425–441, 1991.
90. Ripley, L. S. Frameshift mutation: determinants of specificity. Annu. Rev. Genet., 24: 189–213, 1990.
91. Lambert, I. B., Napolitano, R. L., and Fuchs, R. P. Carcinogen-induced frameshift mutagenesis in repetitive sequences. Proc. Natl. Acad. Sci. USA, 89: 1310–1314, 1992.
92. Aaltonen, L. A., Peltomaki, P., Leach, F. S., et al. Clues to the pathogenesis of familial colorectal cancer. Science (Washington DC), 260: 812–815, 1993.
93. Thibodeau, S. N., Bren, G., and Schaid, D. Microsatellite instability in cancer of the proximal colon. Science (Washington DC), 260: 816–819, 1993.
94. Dunn, J. M., Phillips, R. A., Becker, A. J., and Gallie, B. L. Identification of germline and somatic mutations affecting the retinoblastoma gene. Science (Washington DC), 241: 1797–1800, 1988.
95. Harbour, J. W., Lai, S. L., Whang-Peng, J., Gazdar, A. F., Minna, J. D., and Kaye, F. J. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science (Washington DC), 241: 353–357, 1988.
96. Clore, G. M., Omichinski, J. G., Sakaguchi, K., Zambrano, N., Sakamoto, H., Appella, E., and Gronenborn, A. M. High-resolution solution structure of the oligomerization domain of p53 by multi-dimensional NMR. Science (Washington DC), 265: 386–391, 1994.
97. Cho, Y., Gorina, S., Jeffrey, P., and Pavletich, N. P. Crystal structure of a p53 tumor suppressor-DNA complex: a framework for understanding how mutations inactivate p53. Science (Washington DC), 265: 346–355, 1994.
98. Unger, T., Nau, M. M., Segal, S., and Minna, J. D. p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J., 11: 1383–1390, 1992.
99. Momand, J., Zambetti, G. P., Olson, D. C., George, D., and Levine, A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69: 1237–1245, 1992.
100. Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., and Vogelstein, B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature (Lond.), 362: 857–862, 1993.
101. Chen, J., Marechal, V., and Levine, A. J. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol., 13: 4107–4114, 1993.
102. Brown, D. R., Deb, S., Munoz, R. M., Subler, M. A., and Deb, S. P. The tumor suppressor p53 and the oncoprotein simian virus 40 T-antigen bind to overlapping domains on the MDM2 protein. Mol. Cell. Biol., 13: 6849–6857, 1993.
103. Srinivasan, R., Roth, J. A., and Maxwell, S. A. Sequence-specific interaction of a conformational domain of p53 with DNA. Cancer Res., 53: 5361–5364, 1993.
104. Ruppert, J. M., and Stillman, B. Analysis of a protein-binding domain of p53. Mol. Cell. Biol., 13: 3811–3820, 1993.
105. Sturzbecher, H. W., Brain, R., Addison, C., Rudge, K., Remm, M., Grimaldi, M., Keenan, E., and Jenkins, J. R. A C-terminal α-helix plus basic region motif is the major structural determinant of p53 tetramerization. Oncogene, 7: 1513-1523, 1992.
106. Milner, J., and Medcalf, E. A. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell, 65: 765–774, 1991.
107. Tarunina, M., and Jenkins, J. R. Human p53 binds DNA as a protein homodimer but monomeric variants retain full transcription transactivation activity. Oncogene, 8: 3165–3173, 1993.
108. Pietenpol, J. A., Tokino, T., Thiagalingam, S., El-Deiry, W. S., Kinzler, K. W., and Vogelstein, B. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc. Natl. Acad. Sci. USA, 91: 1998–2002, 1994.
109. Hainaut, P., and Milner, J. Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. Cancer Res., 53: 4469–4473, 1993.
110. Martinez, J., Georgoff, I., and Levine, A. J. Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev., 5: 151–159, 1991.
111. Michalovitz, D., Halevy, O., and Oren, M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell, 62: 671–680, 1990.
112. Reed, M., Wang, Y., Mayr, G., Anderson, M. E., Schwedes, J. F., and Tegtmeyer, P. p53 domains: suppression, transformation, and transactivation. Gene Exp., 3: 95–107, 1993.
113. Davidoff, A. M., Iglehart, J. D., and Marks, J. R. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc. Natl. Acad. Sci. USA, 89: 3439–3442, 1992.
114. Schlichtholz, B., Legros, Y., Gillet, D., Gaillard, C., Marty, M., Lane, D., Calvo, F., and Soussi, T. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res., 52: 6380–6384, 1992.
115. Crawford, L. V., Pim, D. C., and Bulbrook, R. D. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int. J. Cancer, 30: 403–408, 1982.
116. Caron de Fromentel, C., May-Levin, F., Mouriesse, H., Lemerle, J., Chandrasekaran, K., and May, P. Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma. Int. J. Cancer, 39: 185–189, 1987.
117. Lubin, R., Schlichtholz, B., Bengoufa, D., et al. Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res., 53: 5872–5876, 1993.
118. Volkmann, M., Muller, M., Hofmann, W. J., Meyer, M., Hagelstein, J., Rath, U., Kommerell, B., Zentgraf, H., and Galle, P. R. The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy and independent of the α-fetoprotein status. Hepatology, 18: 559–565, 1993.
119. Schuler, G. D., Altschul, S. F., and Lipman, D. J. A workbench for multiple alignment construction and analysis. Proteins, 9: 180–190, 1991.
120. Milne, D. M., Palmer, R. H., and Meek, D. W. Mutation of the casein kinase II phosphorylation site abolishes the anti-proliferative activity of p53. Nucleic Acids Res., 20: 5565–5570, 1992.
121. Fiscella, M., Ullrich, S. J., Zambrano, N., Shields, M. T., Lin, D., Lees-Miller, S. P., Anderson, C. W., Mercer, W. E., and Appella, E. Mutation of the serine 15 phosphorylation site of human p53 reduces the ability of p53 to inhibit cell cycle progression. Oncogene, 8: 1519–1528, 1993.
122. Fiscella, M., Zambrano, N., Ullrich, S. J., Unger, T., Lin, D., Cho, B., Mercer, W. E., Anderson, C. W., and Appella, E. The carboxy-terminal serine 392 phosphorylation site of human p53 is not required for wild-type activities. Oncogene, in press, 1994.
123. Lehman, T. A., Bennett, W. P., Metcalf, R. A., Reddel, R., Welsh, J. A., Ecker, J., Modali, R. V., Ullrich, S., Romano, J. W., Appella, E., Testa, J. R., Gerwin, B. I., and Harris, C. C. p53 mutations, ras mutations and p53-heat shock 70 protein complexes in human lung cell lines. Cancer Res., 51: 4090–4096, 1991.
124. Enomoto, T., Fujita, M., Inoue, M., Rice, J. M., Nakajima, R., Tanizawa, O., and Nomura, T. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium. Cancer Res., 53: 1883–1888, 1993.
125. Shaw, P., Tardy, S., Benito, E., Obrador, A., and Costa, J. Occurrence of Ki-ras and p53 mutations in primary colorectal tumors. Oncogene, 6: 2121–2128, 1991.
126. Kalthoff, H., Schmiegel, W., Roeder, C., et al. p53 and K-RAS alterations in pancreatic epithelial cell lesions. Oncogene, 8: 289–298, 1993.
127. Nikolaidou, A., Liloglou, T., Malliri, A., Ergazaki, M., Tiniakos, G., Tiniakos, D., and Spandidos, D. A. Detection of hepatitis B virus DNA and mutations in K-ras and p53 genes in human hepatocellular carcinomas. Int. J. Oncol., 3: 593-601, 1993.
128. Rodenhuis, S., and Slebos, R. J. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res., 52: 2665s-2669s, 1992.
129. Dowell, S. P., and Hall, P. A. The clinical relevance of the p53 tumour suppressor gene. Cytopathol., 5: 133–145, 1994.
130. Slaughter, T. P., Southwick, H. W., and Smejkel, W. Field cancerization in oral stratified epithelium. Cancer (Phila.), 6: 963–968, 1953.
131. Yin, J., Harpaz, N., Tong, Y., Huang, Y., Laurin, J., Greenwald, B. D., Hontanosas, M., Newkirk, C., and Meltzer, S. J. p53 point mutations in dysplastic and cancerous ulcerative colitis lesions. Gastroenterology, 104: 1633–1639, 1993.
132. Nees, M., Homann, N., Discher, H., Andl, T., Enders, C., Herold-Mende, C., Schuhmann, A., and Bosch, F. X. Expression of mutated p53 occurs in tumor-distant epithelia of head and neck cancer patients: a possible molecular basis for the development of multiple tumors. Cancer Res., 53: 4189–4196, 1993.
133. Chung, K. Y., Mukhopadhyay, T., Kim, J., Casson, A., Ro, J. Y., Goepfert, H., Hong, W. K., and Roth, J. A. Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract. Cancer Res, 53: 1676–1683, 1993.
134. Thor, A. D., Moore, D. H., II, Edgerton, S. M., et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J. Natl. Cancer Inst., 84: 845–855, 1992.
135. Tsuda, H., Iwaya, K., Fukutomi, T., and Hirohashi, S. p53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinomas of high histologic grade. Jpn. J Cancer Res., 84: 394–401, 1993.
136. Murakami, Y., Hayashi, K., Hirohashi, S., and Sekiya, T. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res., 51: 5520–5525, 1991.
137. Nishida, N., Fukuda, Y., Kokuryu, H., Toguchida, J., Yandell, D. W., Ikenega, M., Imura, H., and Ishizaki, K. Role and mutational heterogeneity of the p53 gene in hepatocellular carcinoma. Cancer Res., 53: 368–372, 1993.
138. Kohler, M. F., Kerns, B. J., Humphrey, P. A., Marks, J. R., Bast, R. C., Jr., and Berchuck, A. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet. Gynecol., 81: 643–650, 1993.
139. Teneriello, M. G., Ebina, M., Linnoila, R. I., Henry, M., Nash, J. D., Park, R. C., and Birrer, M. J. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res., 53: 3103–3108, 1993.
140. Vahakangas, K. H., Samet, J. M., Metcalf, R. A., Welsh, J. A., Bennett, W. P., Lane, D. P., and Harris, C. C. Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet, 339: 576–580, 1992.
141. Sundaresan, V., Ganly, P., Hasleton, P., Rudd, R., Sinha, G., Bleehen, N. M., and Rabbitts, P. p53 and chromosome 3 abnormalities, characteristics of malignant lung tumours, are detectable in preinvasive lesions of the bronchus. Oncogene, 7: 1989–1997, 1992.
142. Sozzi, G., Miozzo, M., Donghi, R., Pilotti, S., Cariani, C. T., Pastorino, U., Della Porta, G., and Pierotti, M. A. Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res., 52: 6079–6082, 1992.
143. Nuorva, K., Soini, Y., Kamel, D., Autio-Harmainen, H., Risteli, L., Risteli, J., Vahakangas, K., and Paakko, P. Concurrent p53 expression in bronchial dysplasias and squamous cell lung carcinomas. Am. J. Pathol., 142: 725–732, 1993.
144. Bennett, W. P., Colby, T. V., Vahakangas, K. H., et al. p53 protein accumulates frequently in early bronchial neoplasia. Cancer Res., 53: 4817–4822, 1993.
145. Gusterson, B. A., Anbazhagan, R., Warren, W., Midgely, C., Lane, D. P., O’Hare, M., Stamps, A., Carter, R., and Jayatilake, H. Expression of p53 in premalignant and malignant squamous epithelium. Oncogene, 6: 1785–1789, 1991.
146. Dolcetti, R., Doglioni, C., Maestro, R., Gasparotto, D., Barzan, L., Pastore, A., Romanelli, M., and Boiocchi, M. p53 over-expression is an early event in the development of human squamous-cell carcinoma of the larynx: genetic and prognostic implications. Int. J. Cancer, 52: 178–182, 1992.
147. Coltrera, M. D., Zarbo, R. J., Sakr, W. A., and Gown, A. M. Markers for dysplasia of the upper aerodigestive tract. Suprabasal expression of PCNA, p53, and CK19 in alcohol-fixed, embedded tissue. Am. J Pathol., 141: 817–825, 1992.
148. Ogden, G. R., Lane, D. P., and Chisholm, D. M. p53 expression in dyskeratosis congenita: a marker for oral premalignancy? J. Clin. Pathol., 46: 169–170, 1993.
149. Boyle, J. O., Hakim, J., Koch, W., van der Riet, P., Hruban, R. H., Roa, R. A., Correo, R., Eby, Y. J., Ruppert, J. M., and Sidransky, D. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res., 53: 4477–4480, 1993.
150. Bennett, W. P., Hollstein, M. C., Metcalf, R. A., Welsh, J. A., He, A., Zhu, S., Kusters, I., Resau, J. H., Trump, B. F., Lane, D. P., and Harris, C. C. p53 mutation and protein accumulation during multistage human esophageal carcinogenesis. Cancer Res., 52: 6092–6097, 1992.
151. Sasano, H., Goukon, Y., Nishihira, T., and Nagura, H. In situ hybridization and immunohistochemistry of p53 tumor suppressor gene in human esophageal carcinoma. Am. J. Pathol., 141: 545–550, 1992.
152. Wang, L. D., Hong, J. Y., Qiu, S. L., Gao, H., and Yang, C. S. Accumulation of p53 protein in human esophageal precancerous lesions: a possible early biomarker for carcinogenesis. Cancer Res., 53: 1783–1787, 1993.
153. Fearon, E. R., and Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell, 61: 759–767, 1990.
154. Kikuchi-Yanoshita, R., Konishi, M., Ito, S., et al. Genetic changes of both p53 alleles associated with the conversion from colorectal adenoma to early carcinoma in familial adenomatous polyposis and non-familial adenomatous polyposis patients. Cancer Res., 52: 3965–3971, 1992.
155. Burmer, G. C., Crispin, D. A., Kolli, V. R., Haggitt, R. C., Kulander, B. G., Rubin, C. E., and Rabinovitch, P. S. Frequent loss of a p53 allele in carcinomas and their precursors in ulcerative colitis. Cancer Commun., 3: 167–172, 1991.
156. Burmer, G. C., Rabinovitch, P. S., Haggitt, R. C., Crispin, D. A., Brentnall, T. A., Kolli, V. R., Stevens, A. C., and Rubin, C. E. Neoplastic progression in ulcerative colitis: histology, DNA content, and loss of a p53 allele. Gastroenterology, 103: 1602-1610, 1992.
157. Pignatelli, M., Stamp, G. W., Kafiri, G., Lane, D., and Bodmer, W. F. Over-expression of p53 nuclear oncoprotein in colorectal adenomas. Int. J. Cancer, 50: 683–688, 1992.
158. van den Berg, F. M., Tigges, A. J., Schipper, M. E., den Hartog-Jager, F. C., Kroes, W. G., and Walboomers, J. M. Expression of the nuclear oncogene p53 in colon tumours. J. Pathol., 157: 193–199, 1989.
159. Tsuda, H., and Hirohashi, S. Frequent occurrence of p53 gene mutations in uterine cancers at advanced clinical stage and with aggressive histological phenotypes. Jpn. J. Cancer Res., 83: 1184–1191, 1992.
160. Kohler, M. F., Marks, J. R., Wiseman, R. W., Jacobs, I. J., Davidoff, A. M., Clarke-Pearson, D. L., Soper, J. T., Bast, R. C., Jr., and Berchuck, A. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J. Natl. Cancer Inst., 85: 1513–1519, 1993.
161. Navone, N. M., Troncoso, P., Pisters, L. L., Goodrow, T. L., Palmer, J. L., Nichols, W. W., Von Eschenbach, A. C., and Conti, C. J. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J. Natl. Cancer Inst., 85: 1657–1669, 1993.
162. Fujimoto, K., Yamada, Y., Okijima, E., Kakizoe, T., Sasaki, H., Sugimura, T., and Terada, M. Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res., 52: 1393–1398, 1992.
163. Habuchi, T., Takahashi, R., Yamada, H., et al. Influence of cigarette smoking and schistosomiasis on p53 gene mutation in urothelial cancer. Cancer Res., 53: 3795–3799, 1993.
164. Chiba, I., Takahashi, T., Nau, M. M., D’Amico, D., Curiel, D. T., Mitsudomi, T., Buchhagen, D. L., Carbone, D., Piantadosi, S., Koga, H., Reissman, P. T., Slamon, D. J., Holmes, E. C., and Minna, J. D. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene, 5: 1603-1610, 1990.
165. Lohmann, D., Putz, B., Reich, U., Bohm, J., Prauer, H., and Hofler, H. Mutational spectrum of the p53 gene in human small-cell lung cancer and relationship to clinico-pathological data. Am. J Pathol., 142: 907–915, 1993.
166. Lee, N. K., Ye, Y. W., Chen, J., Li, X., Waber, P. G., and Nisen, P. D. p53, retinoblastoma, and human papillomavirus in squamous cell carcinoma and adjacent normal mucosa of the upper aerodigestive tract. Arch. Otolaryngol. Head Neck Surg., 119: 1125–1131, 1993.
167. Sidransky, D., Mikkelsen, T., Schwechheimer, K., Rosenblum, M. L., Cavanee, W., and Vogelstein, B. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature (Lond.), 355: 846–847, 1992.
168. Hayashi, Y., Yamashita, J., and Yamaguchi, K. Timing and role of p53 gene mutation in the recurrence of glioma. Biochem. Biophys. Res. Commun., 180: 1145–1150, 1991.
169. Gasparini, G., Weidner, N., Maluta, S., Pozza, F., Boracchi, P., Mezzetti, M., Testolin, A., and Bevilacqua, P. Intratumoral microvessel density and p53 protein: correlation with metastasis in head-and-neck squamous-cell carcinoma. Int. J. Cancer, 55: 739–744, 1993.
170. Chin, K. V., Ueda, K., Pastan, I., and Gottesman, M. M. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science (Washington DC), 255: 459–462, 1992.
171. Dameron, K. M., Volpert, O. V., and Bouck, N. Regulation of an angiogenesis inhibitor in human fibroblasts by the p53 tumor suppressor gene. J. Cell Biochem., 18C: 187, 1994.
172. Kihana, T., Tsuda, H., Teshima, S., Okada, S., Matsuura, S., and Hirohashi, S. High incidence of p53 gene mutation in human ovarian cancer and its association with nuclear accumulation of p53 protein and tumor DNA aneuploidy. Jpn. J. Cancer Res., 83: 978–984, 1992.
173. Remvikos, Y., Tominaga, O., Hammel, P., Laurent-Puig, P., Salmon, R. J., Dutrillaux, B., and Thomas, G. Increased p53 protein content of colorectal tumours correlates with poor survival. Br. J. Cancer, 66: 758–764, 1992.
174. Jung, M., Notario, V., and Dritschilo, A. Mutations in the p53 gene in radiation-sensitive and -resistant human squamous carcinoma cells. Cancer Res., 52: 6390–6393, 1992.
175. Brachman, D. G., Beckett, M., Graves, D., Haraf, D., Vokes, E., and Weichselbaum, R. R. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res., 53: 3667–3669, 1993.
176. O’Connor, P. M., Jackman, J., Jondle, D., Bhatia, K., Magrath, I., and Kohn, K. W. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res., 53: 4776–4780, 1993.
177. Harris, C. C. Human tissues and cells in carcinogenesis research. Cancer Res., 47: 1–10, 1987.
178. Chen, T. M., Chen, C. A., Hsieh, C. Y., Chang, D. Y., Chen, Y. H., and Defendi, V. The state of p53 in primary human cervical carcinomas and its effects in human papillomavirus-immortalized human cervical cells. Oncogene, 8: 1511-1518, 1993.
179. Crook, T., Wrede, D., and Vousden, K. H. p53 point mutation in HPV negative human cervical carcinoma cell lines. Oncogene, 6: 873–875, 1991.
180. Scheffner, M., Munger, K., Byrne, J. C., and Howley, P. M. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc. Natl. Acad. Sci. USA, 88: 5523–5527, 1991.
181. Fagin, J. A., Matsuo, K., Karmakar, A., Chen, D. L., Tang, S. H., and Koeffler, H. P. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J. Clin. Invest., 91: 179–184, 1993.
182. Wright, P. A., Lemoine, N. R., Goretzki, P. E., Wyllie, F. S., Bond, J., Hughes, C., Roher, H. D., Williams, E. D., and Wynford-Thomas, D. Mutation of the p53 gene in a differentiated human thyroid carcinoma cell line, but not in primary thyroid tumours. Oncogene, 6: 1693–1697, 1991.
183. Effert, P., McCoy, R., Abdel-Hamid, M., Flynn, K., Zhang, Q., Busson, P., Tursz, T., Liu, E., and Raab-Traub, N. Alterations of the p53 gene in nasopharyngeal carcinoma. J. Virol., 66: 3768–3775, 1992.
184. Spruck, C. H., Tsai, Y. C., Huang, D. P., Yang, A. S., Rideout, W. M., Gonzalez-Zulueta, M., Choi, P., Lo, K. W., Yu, M. C., and Jones, P. A. Absence of p53 gene mutations in primary nasopharyngeal carcinomas. Cancer Res., 52: 4787–4790, 1992.
185. Somers, K. D., Merrick, M. A., Lopez, M. E., Incognito, L. S., Schechter, G. L., and Casey, G. Frequent p53 mutations in head and neck cancer. Cancer Res., 52: 5997–6000, 1992.
186. Stretch, J. R., Gatter, K. C., Ralfkiaer, E., Lane, D. P., and Harris, A. L. Expression of mutant p53 in melanoma. Cancer Res., 51: 5976–5979, 1991.
187. Council on Scientific Affairs, Harmful effects of ultraviolet radiation. JAMA, 262: 380–384, 1989.
188. Reid, T. M., and Loeb, L. A. Mutagenic specificity of oxygen radicals produced by human leukemia cells. Cancer Res., 52: 1082–1086, 1992.
189. Reid, T. M., and Loeb, L. A. Tandem double CC→ TT mutations are produced by reactive oxygen species. Proc. Natl. Acad. Sci. USA, 90: 3904–3907, 1993.
190. Brash, D. E., Rudolph, J. A., Simon, J. A., Lin, A., McKenna, G. J., Baden, H. P., Halperin, A. J., and Ponten, J. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc. Natl. Acad. Sci. USA, 88: 10124–10128, 1991.
191. Nakazawa, H., English, D., Randell, P. L., Nakazawa, K., Martel, N., Armstrong, B. K., and Yamasaki, H. UV and skin cancer: specific p53 gene mutation in normal skin as a biologically relevant exposure measurement. Proc. Natl. Acad. Sci. USA, 91: 360–364, 1994.
192. Tomaletti, S., and Pfeifer, G. P. Slow repair of pyrimidine dimers at p53 mutation hotspots in skin cancer. Science (Washington DC), 263: 1436–1439, 1994.
193. Balch, C. M., Houghton, A. N., and Peters, L. J. Cutaneous melanoma. In: V. T. DeVita, S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, pp. 1612–1662. Philadelphia: J. B. Lippincott Co., 1993.
194. McGregor, J. M., Yu, C. C., Dublin, E. A., Barnes, D. M., Levison, D. A., and MacDonald, D. M. p53 immunoreactivity in human malignant melanoma and dysplastic naevi. Br. J. Dermatol., 128: 606–611, 1993.
195. Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., and Skolnick, M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science (Washington DC), 264: 436–440, 1994.
196. Nebert, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., and Carson, D. A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (Lond.), 368: 753–756, 1994.
197. Beasley, R. P. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer (Phila.), 61: 1942–1956, 1988.
198. Beasley, R. P., Hwang, L. Y., Lin, C. C., and Chien, C. S. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet, 2: 1129–1133, 1981.
199. Koshy, R., and Hofschneider, P. H. Transactivation by hepatitis B virus may contribute to hepatocarcinogenesis. Curr. Top. Microbiol. Immunol., 144: 265–281, 1989.
200. Kim, C. M., Koike, K., Saito, I., Miyamura, T., and Jay, G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature (Lond.), 351: 317-320, 1991.
201. Feitelson, M. A., Zhu, M., Duan, L.-X., and London, W. T. Hepatitis B X antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene, 8: 1109–1117, 1993.
202. Wang, X. W., Forrester, K., Yeh, H., Feitelson, M. A., Gu, J. R., and Harris, C. C. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl. Acad. Sci. USA, 91: 2230–2234, 1994.
203. Wogan, G. N. Aflatoxins as risk factors for hepatocellular carcinoma in humans. Cancer Res., 52: 2114s-2118s, 1992.
204. Bulatao-Jayme, J., Almero, E. M., Castro, M. C., Jardeleza, M. T., and Salamat, L. A. A case-control dietary study of primary liver cancer risk from aflatoxin exposure. Int. J. Epidemiol., 11: 112–119, 1982.
205. Peers, F., Bosch, X., Kaldor, J., Linsell, A., and Pluijmen, M. Aflatoxin exposure, hepatitis B virus infection and liver cancer in Swaziland. Int. J. Cancer, 39: 545-553, 1987.
206. Van Rensburg, S. J., Cook-Mozaffari, P., Van Schalkwyk, D. J., Van der Watt, J. J., Vincent, T. J., and Purchase, I. F. Hepatocellular carcinoma and dietary aflatoxin in Mozambique and Transkei. Br. J. Cancer, 51: 713–726, 1985.
207. Yeh, F. S., Yu, M. C., Mo, C. C., Luo, S., Tong, M. J., and Henderson, B. E. Hepatitis B virus, aflatoxins, and hepatocellular carcinoma in southern Guangxi, China. Cancer Res., 49: 2506–2509, 1989.
208. Bressac, B., Kew, M., Wands, J., and Ozturk, M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature (Lond.), 350: 429–431, 1991.
209. Challen, C., Lunec, J., Warren, W., Collier, J., and Bassendine, M. F. Analysis of the p53 tumor-suppressor gene in hepatocellular carcinomas from Britain. Hepatology, 16: 1362–1366, 1992.
210. Hollstein, M. C., Wild, C. P., Bleicher, F., Chutimataewin, S., Harris, C. C., Srivatanakul, P., and Montesano, R. p53 mutations and aflatoxin B, exposure in hepatocellular carcinoma patients from Thailand. Int. J. Cancer, 53: 51–55, 1993.
211. Li, D., Cao, Y., He, L., Wang, N. J., and Gu, J. Aberrations of p53 gene in human hepatocellular carcinoma from China. Carcinogenesis (Lond.), 14: 169–173, 1993.
212. Oda, T., Tsuda, H., Scarpa, A., Sakamoto, M., and Hirohashi, S. p53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res., 52: 6358–6364, 1992.
213. Debuire, B., Paterlini, P., Pontisso, P., Basso, G., and May, E. Analysis of the p53 gene in European hepatocellular carcinomas and hepatoblastomas. Oncogene, 8: 2303–2306, 1993.
214. Buetow, K. H., Sheffield, V. C., Zhu, M., Zhou, T., Shen, F., Hino, O., Smith, M., McMahon, B. J., Lanier, A. P., London, W. T., Redeker, A. G., and Govindarajan, S. Low frequency of p53 mutations observed in a diverse collection of primary hepatocellular carcinomas. Proc. Natl. Acad. Sci. USA, 89: 9622–9626, 1992.
215. Teramoto, T., Satonaka, K., Kitazawa, S., Fujimori, T., Hayashi, K., and Maeda, S. p53 gene abnormalities are closely related to hepatoviral infections and occur at a late stage of hepatocarcinogenesis. Cancer Res., 54: 231–235, 1994.
216. Fujimoto, Y., Hampton, L. L., Wirth, P. J., Wang, N. J., Xie, J. P., and Thorgeirsson, S. S. Alterations of tumor suppressor genes and allelic losses in human hepatocellular carcinomas in China. Cancer Res., 54: 281–285, 1994.
217. Ross, R. K., Yuan, J. M., Yu, M. C., Wogan, G. N., Qian, G. S., Tu, J. T., Groopman, J. D., Gao, Y. T., and Henderson, B. E. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet, 339: 943–946, 1992.
218. Qian, G. S., Ross, R. K., Yu, M. C., Yuan, J. M., Gao, Y. T., Henderson, B. E., Wogan, G. N., and Groopman, J. D. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol. Biomarkers. Prev., 3: 3–10, 1994.
219. Pfeifer, A. M. A., Cole, K. E., Smoot, D. T., Weston, A., Groopman, J. D., Shields, P. G., Vignaud, J.-M., Juillerat, M., Lipsky, M. M., Trump, B. F., Lechner, J. F., and Harris, C. C. SV40 T-antigen immortalized normal human liver epithelial cells express hepatocyte characteristics and metabolize chemical carcinogens. Proc. Natl. Acad. Sci. USA, 90: 5123–5127, 1993.
220. Autrup, H., Harris, C. C., Wu, S. M., Bao, L. Y., Pei, X. F., Lu, S., Sun, T. T., and Hsia, C. C. Activation of chemical carcinogens by cultured human fetal liver, esophagus and stomach. Chem. Biol. Interact., 50: 15–25, 1984.
221. Aoyama, T., Yamano, S., Guzelian, P. S., Gelboin, H. V., and Gonzalez, F. J. Five of 12 forms of vaccinia virus-expressed human hepatic cytochrome P450 metabolically activate aflatoxin B1. Proc. Natl. Acad. Sci. USA, 87: 4790–4793, 1990.
222. Lin, J. K., Miller, J. A., and Miller, E. C. 2,3-Dihydro-2-(guan-7-yl)-3-hydroxy-aflatoxin B1. a major acid hydrolysis product of aflatoxin B1-DNA or -ribosomal RNA adducts formed in hepatic microsome-mediated reactions and in rat liver in vivo. Cancer Res., 37: 4430–4438, 1977.
223. Essigmann, J. M., Croy, R. G., Nadzan, A. M., Busby, W. F., Jr., Reinhold, V. N., Buchi, G., and Wogan, G. N. Structural identification of the major DNA adduct formed by aflatoxin B1in vitro. Proc. Natl. Acad. Sci. USA, 74: 1870-1874, 1977.
224. McMahon, G., Davis, E. F., Huber, L. J., Kim, Y., and Wogan, G. N. Characterization of c-Ki-ras and N-ras oncogenes in aflatoxin B1-induced rat liver tumors. Proc. Natl. Acad. Sci. USA, 87: 1104–1108, 1990.
225. Levy, D. D., Groopman, J. D., Lim, S. E., Seidman, M. M., and Kraemer, K. H. Sequence specificity of aflatoxin B1-induced mutations in a plasmid replicated in xeroderma pigmentosum and DNA repair proficient human cells. Cancer Res., 52: 5668–5673, 1992.
226. Trottier, Y., Waithe, W. I., and Anderson, A. Kinds of mutations induced by aflatoxin B1in a shuttle vector replicating in human cells transiently expressing cytochrome P4501A2 cDNA. Mol. Carcinog., 6: 140–147, 1992.
227. Aguilar, F., Hussain, S. P., and Cerutti, P. Aflatoxin B1induces the transversion of G to T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc. Natl. Acad. Sci. USA, 90: 8586–8590, 1993.
228. Aguilar, F., Harris, C. C., Sun, T., Hollstein, M., and Cerutti, P. Geographic variation of p53 mutational profile in nonmalignant human liver. Science (Washington DC), 264: 1317–1319, 1994.
229. DeMarini, D. M. Genotoxicity of tobacco smoke and tobacco smoke condensate. Mutat. Res., 114: 59–89, 1983.
230. Shopland, D. R., Eyre, H. J., and Pechacek, T. F. Smoking-attributable cancer mortality in 1991: is lung cancer now the leading cause of death among smokers in the United States? J. Natl. Cancer Inst., 83: 1142–1148, 1991.
231. Doll, R., and Peto, R. Cigarette smoking and bronchial carcinoma: dose and time relationships among regular smokers and lifelong non-smokers. J. Epidemiol. Commun. Health, 32: 303–313, 1978.
232. U.S. Department of Health, Education and Welfare Smoking and Health. In: A Report of the Surgeon General. DHEW Publication No. (PHS) 79–50066, pp. 5–11, 1988.
233. Ronai, Z. A., Gradia, S., Peterson, L. A., and Hecht, S. S. G to A transitions and G to T transversions in codon 12 of the Ki-ras oncogene isolated from mouse lung tumors induced by 4-(methylnitrosamino)-l-(3-pyridyl)-l-butanone (NNK) and related DNA methylating and pyridyloxobutylating agents. Carcinogenesis (Lond.), 14: 2419–2422, 1993.
234. Suzuki, H., Takahashi, T., Kuroishi, T., Suyama, M., Ariyoshi, Y., and Ueda, R. p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking. Cancer Res., 52: 734–736, 1992.
235. Takeshima, Y., Seyama, T., Bennett, W. P., Metcalf, R. A., Welsh, J. A., Akiba, S., Fujihara, M., Hayashi, Y., Yonehara, S., Ito, T., Mizuno, T., Inai, K., Yamakido, M., Nakamura, N., Akiyama, M., Tokuoka, S., Mabuchi, K., Land, C. E., and Harris, C. C. p53 gene mutations in lung cancers from Japanese non-smokers and atomic bomb survivors. Lancet, 342: 1520–1521, 1993.
236. Hanawalt, P., and Mellon, I. Stranded in an active gene. Curr. Biol., 3: 67-69, 1993.
237. Grafstrom, R. C., Fornace, A. J., Jr., Autrup, H., Lechner, J. F., and Harris, C. C. Formaldehyde damage to DNA and inhibition of DNA repair in human bronchial cells. Science (Washington DC), 220: 216–218, 1983.
238. McDowell, E. M., and Trump, B. F. Histogenesis of preneoplastic and neoplastic lesions in tracheobronchial epithelium. Surv. Synth. Pathol. Res., 2: 235–279, 1983.
239. Berendsen, H. H., de Leij, L., Poppema, S., Postmus, P. E., Boes, A., Sluiter, H. J., and The, H. Clinical characterization of non-small-cell lung cancer tumors showing neuroendocrine differentiation features. J. Clin. Oncol., 7: 1614–1620, 1989.
240. Graziano, S. L., Mazid, R., Newman, N., Tatum, A., Oler, A., Mortimer, J. A., Gullo, J. J., DiFino, S. M., and Scalzo, A. J. The use of neuroendocrine immunoper-oxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer. J. Clin. Oncol., 7: 1398–1406, 1989.
241. Takahashi, T., Suzuki, H., Hida, T., Sekido, Y., Ariyoshi, Y., and Ueda, R. The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Oncogene, 6: 1775–1778, 1991.
242. Miller, C. W., Simon, K., Aslo, A., Kok, K., Yokota, J., Buys, C. H. C. M., Terada, M., and Koeffler, H. P. p53 mutations in human lung tumors. Cancer Res., 52: 1695–1698, 1992.
243. D’Amico, D., Carbone, D., and Mitsudomi, T. High frequency of somatically acquired p53 mutations in small cell lung cancer cell lines and tumors. Oncogene, 7: 339–346, 1992.
244. Sameshima, Y., Matsuno, Y., Hirohashi, S., Shimosato, Y., Mizoguchi, H., Sugimura, T., Terada, M., and Yokota, J. Alterations of the p53 gene are common and critical events for the maintenance of malignant phenotypes in small-cell lung carcinoma. Oncogene, 7: 451–457, 1992.
245. Kishimoto, Y., Murakami, Y., Shiraishi, M., Hayashi, K., and Sekiya, T. Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. Cancer Res., 52: 4799–4804, 1992.
246. Lohmann, D., Putz, B., Reich, U., Bohm, J., Prauer, H., and Hofler, H. Mutational spectrum of the p53 gene in human small-cell lung cancer and relationship to clinico-pathological data. Am. J. Pathol., 142: 907–915, 1993.
247. Osann, K. E., Anton-Culver, H., Kurosaki, T., and Taylor, T. Sex differences in lung-cancer risk associated with cigarette smoking. Int. J. Cancer, 54: 44-48, 1993.
248. Jedrychowski, W., Becher, H., Wahrendorf, J., Basa-Cierpialek, Z., and Gomola, K. Effect of tobacco smoking on various histological types of lung cancer. J. Cancer Res. Clin. Oncol., 118: 276–282, 1992.
249. Stockwell, H. G., Goldman, A. L., Lyman, G. H., Noss, C. I., Armstrong, A. W., Pinkham, P. A., Candelora, E. C., and Brusa, M. R. Environmental tobacco smoke and lung cancer risk in nonsmoking women. J Natl. Cancer Inst., 84: 1417–1422, 1992.
250. Blum, A. Curtailing the tobacco pandemic. In: V. T. DeVita, S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principle and Practice of Oncology, pp. 480–491. Philadelphia: J. B. Lippincott, 1993.
251. Szekely, L., Selivanova, G., Magnusson, K. P., Klein, G., and Wiman, K. G. EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins. Proc. Natl. Acad. Sci. USA, 90: 5455–5459, 1993.
252. Nishihira, T., Hashimoto, Y., Katayama, M., Mori, S., and Kuroki, T. Molecular and cellular features of esophageal cancer cells. J. Cancer Res. Clin. Oncol., 119: 441–449, 1993.
253. Blot, W. J., Devesa, S. S., Kneller, R. W., and Fraumeni, J. F., Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA, 265: 1287–1289, 1991.
254. Blot, W. J., Devesa, S. S., and Fraumeni, J. F., Jr. Continuing climb in rates of esophageal adenocarcinoma: an update. JAMA, 270: 1320, 1993.
255. Hartge, P., Silverman, D., Hoover, R., et al. Changing cigarette habits and bladder cancer risk: a case-control study. J. Natl. Cancer Inst., 78: 1119–1125, 1987.
256. Zhang, Z. F., Sarkis, A. S., Cordon-Cardo, C., Dalbagni, G., Melamed, J., Aprikian, A., Pollack, D., Sheinfeld, J., Herr, H. W., Fair, W. R., Reuter, V. E., and Begg, C. Tobacco smoking, occupation, and p53 nuclear overexpression in early stage bladder cancer. Cancer Epidemiol. Biomarkers Prev., 3: 19–24, 1994.
257. Spruck, C. H., III, Rideout, W. M., III, Olumi, A. F., Ohneseit, P. F., Yang, A. S., Tsai, Y. C., Nichols, P. W., Horn, T., Hermann, G. G., Steven, K., Ross, R. K., Yu, M. C., and Jones, P. A. Distinct pattern of p53 mutations in bladder cancer: relationship to tobacco usage. Cancer Res., 53: 1162–1166, 1993.
258. Samet, J. M. Radon and lung cancer. J. Natl. Cancer Inst., 81: 745–757, 1989.
259. Moolgavkar, S. H., Luebeck, E. G., Krewski, D., and Zielinski, J. M. Radon, cigarette smoke, and lung cancer: a re-analysis of the Colorado plateau uranium miners’ data. Epidemiology, 4: 204–217, 1993.
260. Neuberger, J. S. Residential radon exposure and lung cancer: an overview of ongoing studies. Health Phys., 63: 503–509, 1992.
261. Samet, J. M., and Hornung, R. W. Review of radon and lung cancer risk. Risk Anal., 10: 65–75, 1990.
262. Pershagen, G., Akerblom, G., Axelson, O., et al. Residential radon exposure and lung cancer in Sweden. N. Engl. J. Med., 330: 159–164, 1994.
263. Taylor, J. A., Watson, M. A., Devereux, T. R., Michels, R. Y., Saccomanno, G., and Anderson, M. Mutational hotspot in the p53 gene in radon-associated lung tumors from uranium miners. Lancet, 343: 86–87, 1993.
264. Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., and Howley, P. M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell, 63: 1129–1136, 1990.
265. Liang, X. H., Volkmann, M., Klein, R., Herman, B., and Lockett, S. J. Co-localization of the tumor-suppressor protein p53 and human papillomavirus E6 protein in human cervical carcinoma cell lines. Oncogene, 8: 2645–2652, 1993.
266. Srivastava, S., Tong, Y. A., Devadas, K., Zou, Z. Q., Chen, Y., Pirollo, K. F., and Chang, E. H. The status of the p53 gene in human papilloma virus positive or negative cervical carcinoma cell lines. Carcinogenesis (Lond.), 13: 1273–1275, 1992.
267. Crook, T., Wrede, D., Tidy, J. A., Mason, W. P., Evans, D. J., and Vousden, K. H. Clonal p53 mutation in primary cervical cancer: association with human-papilloma-virus-negative tumours. Lancet, 339: 1070–1073, 1992.
268. Borresen, A. L., Helland, A., Nesland, J., Holm, R., Trope, C., and Kaern, J. Papillomaviruses, p53, and cervical cancer. Lancet, 339: 1350–1351, 1992.
269. Fujita, M., Inoue, M., Tanizawa, O., Iwamoto, S., and Enomoto, T. Alterations of the p53 gene in human primary cervical carcinoma with and without human papillomavirus infection. Cancer Res., 52: 5323–5328, 1992.
270. Busby-Earle, R. M., Steel, C. M., Williams, A. R., Cohen, B., and Bird, C. C. Papillomaviruses, p53, and cervical cancer. Lancet, 339: 1350, 1992.
271. Naito, M., Satake, M., Sakai, E., Hirano, Y., Tsuchida, N., Kanzaki, H., Ito, Y., and Mori, T. Detection of p53 gene mutations in human ovarian and endometrial cancers by polymerase chain reaction-single strand conformation polymorphism analysis. Jpn. J. Cancer Res., 83: 1030–1036, 1992.
272. Willey, J. C., and Harris, C. C. Cellular and molecular biological aspects of human bronchogenic carcinogenesis. CRC Crit. Rev. Hematol. Oncol., 10: 181-209, 1990.
273. Jones, P. A., Buckley, J. D., Henderson, B. E., Ross, R. K., and Pike, M. C. From gene to carcinogen: a rapidly evolving field in molecular epidemiology. Cancer Res., 51: 3617–3620, 1991.
274. Nagase, H., and Nakamura, Y. Mutations of the APC gene. Hum. Mutat., 2: 425–434, 1993.
275. Giannelli, F., Green, P. M., High, K. A., et al. Haemophilia B: database of point mutations and short additions and deletions—fourth edition, 1993. Nucleic Acids Res., 21: 3075–3087, 1993.
276. Sugimura, T. Studies on environmental chemical carcinogenesis in Japan. Science (Washington DC), 233: 312–318, 1986.
277. Zielenska, M., Beranek, D., and Guttenplan, J. B. Different mutational profiles induced by N-nitroso-N-ethylurea: effects of dose and error-prone DNA repair and correlations with DNA adducts. Environ. Mol. Mutagen., 11: 473–485, 1988.
278. Singer, B. In vivo formation and persistence of modified nucleosides resulting from alkylating agents. Environ. Health Perspect., 62: 41–48, 1985.
279. Pegg, A. E. Methylation of the O6position of guanine in DNA is the most likely initiating event in carcinogenesis by methylating agents. Cancer Invest., 2: 223–231, 1984.
280. Sasa, M., Kondo, K., Komaki, K., Uyama, T., Morimoto, T., and Monden, Y. Frequency of spontaneous p53 mutations (CpG site) in breast cancer in Japan. Breast. Cancer Res. Treat., 27: 247–252, 1993.
281. de Jong, P. J., Grosovsky, A. J., and Glickman, B. W. Spectrum of spontaneous mutation at the APRT locus of Chinese hamster ovary cells: an analysis at the DNA sequence level. Proc. Natl. Acad. Sci. USA, 85: 3499–3503, 1988.
282. Drobetsky, E. A., Grosovsky, A. J., and Glickman, B. W. The specificity of UV-induced mutations at an endogenous locus in mammalian cells. Proc. Natl. Acad. Sci. USA, 84: 9103–9107, 1987.
283. Mazur, M., and Glickman, B. W. Sequence specificity of mutations induced by benzo[a]pyrene-7,8-diol-9,10-epoxide at endogenous aprt gene in CHO cells. Somat. Cell Mol. Genet., 14: 393–400, 1988.
284. Halevy, O., Rodel, J., Peled, A., and Oren, M. Frequent p53 mutations in chemically induced murine fibrosarcoma. Oncogene, 6: 1593–1600, 1991.
285. Lozano, J. C., Nakazawa, H., Cros, M. P., Cabral, R., and Yamasaki, H. G→A mutations in p53 and Ha-ras genes in esophageal papillomas induced by N-nitrosomethylbenzylamine in two strains of rats. Mol. Carcinog., 9: 33–39, 1994.
286. Smith, M. L., Yeleswarapu, L., Scalamogna, P., Locker, J., and Lombardi, B. p53 mutations in hepatocellular carcinomas induced by a choline-devoid diet in male Fischer-344 rats. Carcinogenesis (Lond.), 14: 503–510, 1993.
287. Hegi, M. E., Soderkuist, P., Foley, J. F., et al. Characterization of p53 mutations in methylene chloride-induced lung tumors from B6C3F1 mice. Carcinogenesis (Lond.), 14: 803–810, 1993.
288. Goodrow, T. L., Storer, R. D., Leander, K. R., et al. Murine p53 intron sequence 5–8 and their use in polymerase chain reaction/direct sequencing analysis of p53 mutations in CD-1 mouse liver and lung tumors. Mol. Carcinog., 5: 9–15, 1992.